Latest updates on macituximab/magenex in 2025

Margetuximab, as a new type of humanized monoclonal antibody, has received widespread attention in the treatment of HER2-positive breast cancer in recent years. In 2025, there will be some new developments in the global and domestic markets, mainly focusing on clinical applications, research expansion and regulatory developments. Margetuximab improves antibody-dependent cell-mediated cytotoxicity (ADCC) by enhancing the recognition of HER2-positive tumor cells by immune effector cells, and has the potential to improve efficacy compared with traditional Herceptin (Trastuzumab).

In the international market,the latest research in 2025 continues to focus on its application in advanced HER2-positive breast cancer and gastric cancer, while exploring combinations with PD-1/PD-L1 inhibitors and chemotherapy drugs. Multicenter clinical trials have shown that margituximab combined with chemotherapy or immunotherapy can prolong progression-free survival in patients with drug resistance or relapse, and further verified its safety and tolerability. Overseas markets are also continuing to expand drug accessibility, including the supply of European and Japanese versions of original drugs, allowing more patients to obtain innovative drug treatment opportunities in different treatment settings.

In China, margituximab has recently been approved for marketing, indicating that Chinese patients with HER2-positive tumors can directly benefit from this new type of monoclonal antibody therapy. However, due to the short time on the market, clinical application experience is still in the accumulation stage. The latest guidelines in 2025 recommend that during treatment with margetuximab, doctors should formulate a plan based on the patient's HER2 expression level, previous treatment history, and drug resistance. In addition, the long-term efficacy of the drug and the combination treatment strategy still require further follow-up studies to evaluate the actual application effect in different populations.

Reference materials:https://www.margenza.com/